CHOP (DDIT3) Breakapart
Myxoid liposarcoma (MLS) is the most common subtype of liposarcoma1. The TLS-CHOP (FUS-DDIT3) t(12;16)(q13.3;p11) fusion gene, firstly described by Turc-Carel et al. in 19862, is now well established and is present in at least 95% of MLS3.
In rare cases, an EWS-CHOP (EWSR1-DDIT3) t(12;22)(q13;q12) translocation has been described4. The transcription factor gene, CHOP (DDIT3) (CREBP-homologous protein/DNA damage inducible transcript 3), is a negative regulator of adipocyte differentiation5.
The TLS (Translocated in Liposarcoma)6 or FUS7 gene is a nuclear RNA-binding protein with extensive sequence similarity to EWS. The TLS-CHOP protein interferes with adipocyte differentiation and favours proliferation over terminal differentiation4.
1. Enzinger and Weiss, Soft Tissue Tumors 3rd Ed. St Louis; MO:Mosby, 1995
2. Turc-Carel et al., Can Genet Cytogenet 1986;23:291-9
3. Mitelman, Catalog of chromosome aberrations in cancer. 5th Ed. 1995 New York: WileyLiss, Inc. 1994
4. Antonescu et al., Clin Canc Res 2001;7:3977-87
5. Hunag et al., Biol Open. 2012 Aug 15;1(8):705-10
6. Crozat et al., Nature 1993;363:640-4
7. Rabbitts et al., Nat Genet 1993;4:175-80
- Area of Interest*
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.